Patient Square Capital has led a series B round for the Stanford-linked gene therapy developer, which previously collected $80.5m in May last year.
Kriya Therapeutics, a US-based developer of gene therapies based on research at Stanford University, has closed a $100m series B round led by investment firm Patient Square Capital.
The transaction featured pharmaceutical firm Dexcel Pharma, QVT Financial, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
Woodline Partners LP, CAM Capital, Hongkou Capital, Alumni Ventures and a range of other new but unnamed investors also participated.
Founded in 2019, Kriya Therapeutics is working on a fully integrated platform that it hopes will reduce both the time it takes to get a gene therapy to market and the cost per dose.
It started out with a focus on type 1 and type 2 diabetes, as well as severe obesity, but has since built a diversified pipeline of assets, covering rare and prevalent metabolic, ophthalmic and oncologic diseases.
John Wright, professor of paediatrics in the Center for Definitive and Curative Medicine at Stanford University, is Kriya’s scientific co-founder and chief scientific adviser.
The latest cash injection has been allocated to further platform development. It will also allow Kriya to expand its pipeline and progress existing candidates.
Jim Momtazee, managing partner of Patient Square Capital, will join Kriya’s board of directors. Momtazee also recently joined the board of Apollo Therapeutics when the biopharmaceutical joint venture raised $145m earlier this month.
Kriya raised an $80.5m series A round in May 2020 backed by QVT Financial, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Asia Alpha, Dexcel Pharma and angel investor Paul Manning.
Transhuman Capital also took part in the series A round, having supplied an undisclosed amount of seed funding at the time of Kriya’s launch.
